Skip to main content

Table 1 Baseline characteristic of 16 patients with eosinophilic granulomatosis with polyangiitis

From: Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis

  Pre-MPZ (n = 16) Post–MPZ (n = 16) P value*
Clinical manifestations at diagnosis, n (%) Asthma 16 (100), general 10 (62.5), cutaneous 8 (50.0), ENT 5 (31.3), chest 8 (50.0), cardiomyopathy 3 (18.8), abdominal 1 (6.3), neuropathy 8 (50.0), ANCA positive status 5 (31.3), biopsy findings 12 (75)  
Male/female/age at MPZ introduction 7/9/61.5 [53.3–70.5]  
Disease duration (months) at MPZ introduction 54 [22–144]  
Treatment history, n (%) CS pulse 2 (12.5), high-dose CS 14 (87.5), low-dose CS 2 (12.5), IVCY 9 (56.3), IVIG 6 (37.5), RTX 1 (6.3), MTX 6 (37.5), AZ 12 (75.0), TAC 1 (6.3)  
Relapsing/refractory/remission, n (%) 4 (25.0)/11 (68.7)/1 (6.3) 10 (62.5)/6 (37.5)/0 (0) ND
Concomitant CS dose (PSL mg/day) 8.0 [5.0–11.5] 6.5 [2.6–10.0] 0.2012
Concomitant CS < 4 mg/day (PSL), n (%) 3 (18.8) 5 (31.3) 0.1573
Concomitant immunosuppressant, n (%) AZ 6 (37.5), MTX 5 (31.3), TAC 1 (6.3) AZ 6 (37.5), MTX 4 (25.0), TAC 1 (6.3)  
Without immunosuppressant, n (%) 6 (37.5) 7 (43.8) 0.3173
BVAS 0 [0–2.0] 1.0 [0–3.8] 0.1084
BVAS > 0, n (%) 4 (25.0) 8 (50.0) 0.3173
BVAS items Asthma 2 (12.5), sinonasal 2 (12.5), chest 1 (6.3) Asthma 6 (37.5), general 1 (6.3), cutaneous 2 (12.5), sinonasal 2 (12.5), chest 3 (18.8),  
VDI 3.5 [3.0–4.8] 4.0 [3.0–5.8] 0.5577
VDI items Chronic bronchial asthma 16 (100), chronic respiratory failure 1 (6.3), abnormal respiratory function 7 (43.8), old myocardial infarction 2 (12.5), cardiomyopathy 2 (12.5), low vision 1 (6.3), chronic sinusitis 6 (37.5), deafness 3 (18.8), peripheral neuropathy 8 (50.0), diabetes 4 (25), hypertension 4 (25), osteoporosis 5 (31.3), other 3 (18.8) Chronic bronchial asthma 16 (100), chronic respiratory failure 1 (6.3), abnormal respiratory function 8 (50.0), old myocardial infarction 2 (12.5), cardiomyopathy 2 (12.5), low vision 1 (6.3), chronic sinusitis 7 (43.8), deafness 3 (18.8), peripheral neuropathy 8 (50.0), diabetes 4 (25), hypertension 4 (25), osteoporosis 5 (31.3), other 5 (31.3)  
ANCA-positive status, n (%) 0 (0) 1 (6.3) ND
Absolute eosinophil count (/μL) 178.6 [48.7–370.2] 183 [60.0–2479] 0.1591
CRP (mg/dL) 0.06 [0.03–0.09] 0.09 [0.05–0.24] 0.0593
  1. CS corticosteroid (prednisolone or equivalent), IVCY cyclophosphamide pulse therapy i.v., RTX rituximab, MTX methotrexate, AZ azathioprine, TAC tacrolimus, BVAS Birmingham Vasculitis Activity Score, VDI vasculitis damage index, ND not detected by McNemar test. Data are shown by median [quartile] or n (%). P values were determined by McNemar test or Wilcoxon signed-rank test. *P < 0.05: Pre-MPZ (n = 16) vs. Post-MPZ (n = 16)